---
provider: falcon
model: Edison Scientific Literature
cached: false
start_time: '2025-12-17T23:25:34.443713'
end_time: '2025-12-17T23:32:53.553652'
duration_seconds: 439.11
template_file: templates/disease_pathophysiology_research.md
template_variables:
  disease_name: Endometriosis
  mondo_id: ''
  category: Complex
provider_config:
  timeout: 600
  max_retries: 3
  parameters:
    allowed_domains: []
    temperature: 0.1
citation_count: 12
---

## Question

# Disease Pathophysiology Research Template

## Target Disease
- **Disease Name:** Endometriosis
- **MONDO ID:**  (if available)
- **Category:** Complex

## Research Objectives

Please provide a comprehensive research report on the pathophysiology of **Endometriosis**.
Focus on the molecular and cellular mechanisms underlying disease progression.

### Required Information

#### 1. Core Pathophysiology
- What are the primary pathophysiological mechanisms?
- What molecular pathways are dysregulated?
- What cellular processes are affected?

#### 2. Key Molecular Players
- **Genes/Proteins**: Which genes are causally involved or implicated?
- **Chemical Entities**: What metabolites, drugs, or small molecules are relevant?
- **Cell Types**: Which cell types are primarily affected?
- **Anatomical Locations**: Which tissues/organs are involved?

#### 3. Biological Processes (for GO annotation)
- What biological processes (GO terms) are disrupted?
- Consider: signaling pathways, metabolic processes, cellular responses, transport, etc.

#### 4. Cellular Components
- Where in the cell do key processes occur?
- Consider: organelles, membrane compartments, extracellular space, etc.

#### 5. Disease Progression
- What is the sequence of events from initial trigger to clinical manifestation?
- Are there distinct stages or phases?

#### 6. Phenotypic Manifestations
- What are the key clinical phenotypes?
- How do they relate to the underlying mechanisms?

### Citation Requirements

- Cite primary literature (PMID preferred) for all mechanistic claims
- Prioritize recent reviews and landmark papers
- Include direct quotes where possible to support key statements

### Output Format

Structure your response as a narrative that could be used to populate a disease knowledge base entry with:
- Pathophysiology description
- Gene/protein annotations with ontology terms (HGNC, GO)
- Phenotype associations (HP terms)
- Cell type involvement (CL terms)
- Anatomical locations (UBERON terms)
- Chemical entities (CHEBI terms)
- Evidence items with PMIDs


## Output

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.

# Disease Pathophysiology Research Template

## Target Disease
- **Disease Name:** Endometriosis
- **MONDO ID:**  (if available)
- **Category:** Complex

## Research Objectives

Please provide a comprehensive research report on the pathophysiology of **Endometriosis**.
Focus on the molecular and cellular mechanisms underlying disease progression.

### Required Information

#### 1. Core Pathophysiology
- What are the primary pathophysiological mechanisms?
- What molecular pathways are dysregulated?
- What cellular processes are affected?

#### 2. Key Molecular Players
- **Genes/Proteins**: Which genes are causally involved or implicated?
- **Chemical Entities**: What metabolites, drugs, or small molecules are relevant?
- **Cell Types**: Which cell types are primarily affected?
- **Anatomical Locations**: Which tissues/organs are involved?

#### 3. Biological Processes (for GO annotation)
- What biological processes (GO terms) are disrupted?
- Consider: signaling pathways, metabolic processes, cellular responses, transport, etc.

#### 4. Cellular Components
- Where in the cell do key processes occur?
- Consider: organelles, membrane compartments, extracellular space, etc.

#### 5. Disease Progression
- What is the sequence of events from initial trigger to clinical manifestation?
- Are there distinct stages or phases?

#### 6. Phenotypic Manifestations
- What are the key clinical phenotypes?
- How do they relate to the underlying mechanisms?

### Citation Requirements

- Cite primary literature (PMID preferred) for all mechanistic claims
- Prioritize recent reviews and landmark papers
- Include direct quotes where possible to support key statements

### Output Format

Structure your response as a narrative that could be used to populate a disease knowledge base entry with:
- Pathophysiology description
- Gene/protein annotations with ontology terms (HGNC, GO)
- Phenotype associations (HP terms)
- Cell type involvement (CL terms)
- Anatomical locations (UBERON terms)
- Chemical entities (CHEBI terms)
- Evidence items with PMIDs


# Disease Pathophysiology Research Template

## Target Disease
- Disease Name: Endometriosis
- MONDO ID: MONDO:0005263
- Category: Complex

## Pathophysiology description (narrative synthesis)
Endometriosis is an estrogen‑dependent, chronic inflammatory condition in which endometrial‑like glands and stroma establish at ectopic sites, most commonly on the peritoneum and ovary. Current models integrate retrograde menstruation with permissive host factors—genetic susceptibility, altered endometrial biology, immune dysregulation, hypoxia‑driven angiogenesis, neuroangiogenesis, and progressive fibrotic remodeling. The disease affects about 10% of reproductive‑aged women worldwide, with a diagnostic delay of approximately 7–9 years, contributing to substantial pain and infertility burden (papandreouUnknownyearinterinstitutionalinterdepartmentalmasterof pages 7-15). Lesions display estrogen dominance and progesterone resistance, supported by local estrogen biosynthesis (aromatase/CYP19A1; reductive HSD17B1 with reduced oxidative HSD17B2) and diminished progesterone receptor signaling; hypoxia and HIF‑1α amplify VEGF‑mediated angiogenesis and inflammatory circuits. Immune alterations include macrophage reprogramming, reduced NK cytotoxicity, T‑cell imbalance, and elevated pro‑inflammatory cytokines (e.g., IL‑6, TNF‑α), enabling immune evasion and lesion persistence. Warburg‑like metabolic reprogramming, EMT/TGF‑β‑driven fibrosis, and extracellular matrix (ECM) remodeling consolidate chronicity. Somatic alterations (ARID1A, PIK3CA, KRAS, PTEN) occur in some lesions and are implicated in the small but real risk of malignant transformation to endometriosis‑associated ovarian cancer. Single‑cell/spatial transcriptomics and large‑scale genetics highlight disease‑relevant stromal and immune cell states and suggest polygenic risk acting through immune regulation, cell differentiation, and hormone pathways (sarsenova2025molecularandcellular pages 10-14, adilbayeva2024pathogenesisofendometriosis pages 14-15, sarsenova2025molecularandcellular pages 14-17).

| Axis | Key genes/proteins (HGNC) | Perturbed processes (GO / plain text) | Primary cell types (CL / plain text) | Anatomical locations (UBERON / plain text) | Chemical entities (CHEBI / plain text) | Representative evidence |
|---|---|---|---|---|---|---|
| Estrogen dominance & progesterone resistance | ESR1, ESR2, PGR | Steroid hormone signaling; altered receptor expression (progesterone response) | Endometrial epithelial cells, stromal cells | Uterine endometrium; peritoneum (ectopic sites) | Estradiol (E2), Progesterone (P4) | https://doi.org/10.69622/28227977 (sarsenova2025molecularandcellular pages 14-17) |
| Local estrogen biosynthesis (aromatase / HSD17B / sulfatase) | CYP19A1, HSD17B1, HSD17B2, STS | Local steroid biosynthesis and activation/inactivation of estrogens | Stromal cells, epithelial cells | Endometriotic lesions, eutopic endometrium | Androstenedione/testosterone → estrone/estradiol; estrogen-sulfates | https://doi.org/10.3389/fphar.2023.1155558 (sarsenova2025molecularandcellular pages 10-14) |
| Hypoxia / HIF-1 / VEGF angiogenesis & neuroangiogenesis | HIF1A, VEGFA, EPAS1 | Hypoxia response, angiogenesis, vascular development | Endothelial cells, stromal fibroblasts, perivascular cells | Lesion microenvironment, peritoneum, ovary (endometrioma) | VEGF (growth factor); hypoxia-induced metabolites | https://doi.org/10.3390/ijms25147624 (adilbayeva2024pathogenesisofendometriosis pages 14-15) |
| Immune dysregulation (macrophages, NK, T cells, cytokines, checkpoints) | IL6, TNF, CCL2, PDCD1 (PD-1), CTLA4 | Inflammatory signaling, immune evasion, cytokine-mediated recruitment | Macrophages (M1/M2-like), NK cells, CD4+/CD8+ T cells, Tregs | Peritoneal cavity, lesion stroma | Pro-inflammatory cytokines (IL-6, TNF-α), chemokines | https://doi.org/10.7759/cureus.87091 (ahmed2025exploringtheimmune pages 15-16) |
| Fibrosis / EMT / TGF-β / ECM remodeling | TGFB1, TGFBI, MMP1, MMP2 | Extracellular matrix organization, epithelial–mesenchymal transition, fibrosis | Stromal fibroblasts, myofibroblasts, mesenchymal cells | Lesions, adhesions, affected peritoneum | Collagen, fibronectin; TGF-β signaling molecules | https://doi.org/10.69622/28227977 (sarsenova2025molecularandcellular pages 10-14) |
| Metabolic reprogramming (Warburg-like) | SLC2A1 (GLUT1), HK2, PDK1 | Glycolysis upregulation, altered mitochondrial function, ROS metabolism | Lesion stromal/epithelial cells, macrophages | Ectopic lesions (hypoxic niches) | Glucose, lactate, reactive oxygen species (ROS) | https://doi.org/10.69622/28227977 (sarsenova2025molecularandcellular pages 10-14) |
| Somatic driver mutations & malignant transformation risk | ARID1A, PIK3CA, KRAS, PTEN | DNA repair/PI3K signaling / oncogenic activation | Epithelial cells of lesions (clonal populations) | Ovarian endometrioma → risk for EAOC (clear cell, endometrioid) | DNA damage products; ROS | https://doi.org/10.3390/ijms25147624 (adilbayeva2024pathogenesisofendometriosis pages 14-15) |
| GWAS / germline risk architecture | Multiple risk loci (incl. loci near ESR1) | Genetic susceptibility; regulation of immune, hormonal, proliferative pathways | Decidualized stromal cells, macrophages (cell-context from atlas) | Uterine tissues; systemic genetic risk | — (polygenic risk) | https://doi.org/10.69622/28227977 (sarsenova2025molecularandcellular pages 10-14) |
| Microbiome / estrobolome contributions | Bacterial β-glucuronidase (functional) | Estrogen recycling (deconjugation), modulation of inflammation | Gut microbiota; reproductive-tract microbiota | Gut, vagina, endometrium | Microbial metabolites (SCFAs), estrogen-sulfates | https://doi.org/10.69622/28227977 (sarsenova2025molecularandcellular pages 10-14) |
| Single-cell & spatial niche insights | CXCL12, MRC1, APOE (cell-state markers) | Cell–cell signaling, immune–stromal interactions, angiogenic niches | Stromal subtypes, epithelial subtypes, lesion-resident macrophages | Lesion microenvironment (spatially organized niches) | Chemokines (CXCL12), lipids (ApoE-associated) | https://doi.org/10.69622/28227977 (sarsenova2025molecularandcellular pages 10-14) |
| Disease progression sequence (mechanistic) | — (process-level) | Retrograde menstruation → implantation → immune evasion → angiogenesis & innervation → fibrosis | Shed endometrial epithelial & stromal cells; recruited immune cells | Peritoneal surfaces, ovary, pelvic organs | Hemoglobin/iron (from bleed) → ROS; prostaglandins (PGE2) | https://doi.org/10.69622/28227977 (sarsenova2025molecularandcellular pages 10-14) |
| Clinical phenotypes & burden | — (clinical manifestations) | Pain signaling, impaired fertility, systemic comorbidity | N/A (multicellular) | Pelvis, reproductive organs; systemic symptoms | Analgesics, hormonal modulators (therapeutics) | Prevalence ~10%; diagnostic delay median ~7–9 yrs — https://doi.org/10.69622/28227977 (papandreouUnknownyearinterinstitutionalinterdepartmentalmasterof pages 7-15) |


*Table: Compact, ontology-style summary linking major pathophysiology axes to genes, processes, cell types, anatomical sites, chemical entities and representative evidence (DOI + context ID); useful as a knowledge-base import or quick reference for mechanistic claims.*

## 1. Core Pathophysiology
- Primary mechanisms:
  - Retrograde menstruation provides endometrial fragments that implant at ectopic sites (“seed and soil”), where local hypoxia, estrogen excess, and immune dysfunction favor survival and growth (sarsenova2025molecularandcellular pages 10-14, sarsenova2025molecularandcellular pages 14-17).
  - Estrogen dominance/progesterone resistance: increased ERβ:ERα ratio and reduced PR, plus upregulated aromatase (CYP19A1) and 17β‑HSD imbalance (↑HSD17B1, ↓HSD17B2) sustain local E2 and blunt decidualization (sarsenova2025molecularandcellular pages 14-17). Quote: “increased aromatase… and reduced expression of the E2‑inactivating enzyme HSD17B2” (URL: https://doi.org/10.69622/28227977) (sarsenova2025molecularandcellular pages 14-17).
  - Hypoxia/HIF‑1α/VEGF: lesion hypoxia stabilizes HIF‑1α, upregulating VEGF and inflammatory mediators, promoting angiogenesis and neuroangiogenesis (adilbayeva2024pathogenesisofendometriosis pages 14-15). Quote: “iron‑induced oxidative stress… activate NF‑κB, and upregulate VEGF, promoting angiogenesis/neoangiogenesis” (DOI: 10.3390/ijms25147624) (adilbayeva2024pathogenesisofendometriosis pages 14-15).
  - Immune dysregulation: macrophage‑dominated microenvironment with impaired clearance of refluxed cells, reduced NK cytotoxicity, T‑cell imbalance, and elevated IL‑6/TNF‑α facilitating immune evasion and pain (ahmed2025exploringtheimmune pages 15-16). Quote: “dysregulated innate immunity, particularly impaired cytotoxic function of natural killer (NK) cells” (URL: https://doi.org/10.7759/cureus.87091) (ahmed2025exploringtheimmune pages 15-16).
  - Fibrosis/EMT/TGF‑β and ECM remodeling drive adhesion formation and deep infiltrating phenotypes (sarsenova2025molecularandcellular pages 10-14).
  - Metabolic reprogramming: hypoxia‑adapted glycolysis/Warburg‑like metabolism in lesions (sarsenova2025molecularandcellular pages 10-14).

- Dysregulated molecular pathways: estrogen biosynthesis and signaling (CYP19A1/HSD17B1/HSD17B2; ESR1/ESR2; PGR), hypoxia/HIF‑1/VEGF, NF‑κB‑mediated inflammation, TGF‑β/EMT/ECM, PI3K/AKT from somatic drivers, and immune checkpoint axes (PD‑1/CTLA4) in immune suppression (adilbayeva2024pathogenesisofendometriosis pages 14-15, sarsenova2025molecularandcellular pages 14-17, ahmed2025exploringtheimmune pages 15-16).

- Affected cellular processes: implantation/adhesion, angiogenesis and neurogenesis, aberrant stromal–epithelial signaling and decidualization, ECM deposition, immune cell recruitment and polarization, altered glycolysis/ROS handling (sarsenova2025molecularandcellular pages 10-14, adilbayeva2024pathogenesisofendometriosis pages 14-15, ahmed2025exploringtheimmune pages 15-16).

## 2. Key Molecular Players
- Genes/Proteins (HGNC):
  - Steroidogenesis and receptors: CYP19A1 (aromatase), HSD17B1/HSD17B2, ESR1/ESR2, PGR (sarsenova2025molecularandcellular pages 10-14, sarsenova2025molecularandcellular pages 14-17).
  - Hypoxia/angiogenesis: HIF1A, VEGFA (adilbayeva2024pathogenesisofendometriosis pages 14-15).
  - Inflammation/immune: IL6, TNF, CCL2; immune checkpoints PDCD1 (PD‑1), CTLA4 (ahmed2025exploringtheimmune pages 15-16).
  - Fibrosis/ECM/EMT: TGFB1, TGFBI, MMPs (sarsenova2025molecularandcellular pages 10-14).
  - Somatic drivers: ARID1A, PIK3CA, KRAS, PTEN (adilbayeva2024pathogenesisofendometriosis pages 14-15).

- Chemical entities (CHEBI): estradiol (E2), progesterone (P4), prostaglandin E2 (PGE2), VEGF as growth factor ligand, ROS/iron byproducts (adilbayeva2024pathogenesisofendometriosis pages 14-15, sarsenova2025molecularandcellular pages 14-17).

- Cell types (CL): endometrial epithelial and stromal cells; endothelial cells; peritoneal/lesion‑resident macrophages (M2‑like, scar‑associated); NK cells; CD4+/CD8+ T cells; Tregs (ahmed2025exploringtheimmune pages 15-16, sarsenova2025molecularandcellular pages 10-14).

- Anatomical locations (UBERON): uterine endometrium, peritoneum, ovary (endometrioma), pelvic peritoneal surfaces; adhesions across pelvic organs (sarsenova2025molecularandcellular pages 10-14, papandreouUnknownyearinterinstitutionalinterdepartmentalmasterof pages 7-15).

## 3. Biological Processes (GO annotation, representative)
- GO:0030335 positive regulation of cell migration; GO:0001525 angiogenesis; GO:0001666 response to hypoxia; GO:0030198 ECM organization; GO:0034097 response to cytokine; GO:0006694 steroid biosynthetic process; GO:0030509 BMP signaling; GO:0030512 negative regulation of TGF‑β receptor signaling (context‑dependent); GO:0042110 T cell activation; GO:0006954 inflammatory response (sarsenova2025molecularandcellular pages 10-14, adilbayeva2024pathogenesisofendometriosis pages 14-15, ahmed2025exploringtheimmune pages 15-16).

## 4. Cellular Components (where processes occur)
- Cytoplasm/nucleus for steroid receptor signaling (ESR1/ESR2, PGR); endoplasmic reticulum for aromatase; mitochondria and cytosol for glycolysis/ROS; plasma membrane and extracellular space for cytokines/VEGF; ECM (collagen/fibronectin) for remodeling; vascular niche for angiogenesis; peritoneal fluid compartment for immune mediators (sarsenova2025molecularandcellular pages 10-14, adilbayeva2024pathogenesisofendometriosis pages 14-15, ahmed2025exploringtheimmune pages 15-16).

## 5. Disease Progression
- Sequence of events: retrograde menstruation → attachment/implantation on peritoneum → immune evasion via macrophage‑rich, NK‑suppressed microenvironment and cytokines → hypoxia‑driven HIF‑1α/VEGF angiogenesis and neuroangiogenesis → local estrogen amplification and progesterone resistance → EMT/myofibroblast activation and ECM deposition → adhesions and deep infiltrating lesions; chronic cyclic bleeding sustains iron‑driven oxidative stress and fibrosis (sarsenova2025molecularandcellular pages 10-14, adilbayeva2024pathogenesisofendometriosis pages 14-15, ahmed2025exploringtheimmune pages 15-16).

## 6. Phenotypic Manifestations and links to mechanisms
- Clinical phenotypes (HPO): chronic pelvic pain (HP:0012531), dysmenorrhea (HP:0002360), dyspareunia (HP:0030019), dyschezia (HP:0012552), dysuria/pain with urination (HP:0100518), subfertility/infertility (HP:0000823). Pain relates to neuroangiogenesis and inflammatory cytokines; infertility relates to impaired endometrial receptivity/decidualization, altered immune tolerance, adhesions, and ovarian reserve effects of endometriomas (ahmed2025exploringtheimmune pages 15-16, sarsenova2025molecularandcellular pages 10-14, papandreouUnknownyearinterinstitutionalinterdepartmentalmasterof pages 7-15).

## Gene/protein annotations with ontology terms (examples)
- CYP19A1 (HGNC:2594): GO:0004501 aromatase activity; GO:0006694 steroid biosynthetic process; cellular component: endoplasmic reticulum membrane; Evidence: increased aromatase in EcE/EuE, therapeutic target (sarsenova2025molecularandcellular pages 10-14).
- HSD17B1 (HGNC:5217) / HSD17B2 (HGNC:5218): GO:0003855/GO:0008406 17β‑hydroxysteroid dehydrogenase activity; process: estrogen activation/inactivation; Evidence: imbalance supports E2 dominance (sarsenova2025molecularandcellular pages 14-17).
- HIF1A (HGNC:4910): GO:0001666 response to hypoxia; GO:0001525 angiogenesis; Evidence: hypoxia in lesions upregulates VEGF and inflammatory mediators (adilbayeva2024pathogenesisofendometriosis pages 14-15).
- VEGFA (HGNC:12680): GO:0001525 angiogenesis; extracellular space; Evidence: upregulated downstream of HIF‑1α in lesions (adilbayeva2024pathogenesisofendometriosis pages 14-15).
- IL6 (HGNC:6018), TNF (HGNC:11892): GO:0006954 inflammatory response; extracellular region; Evidence: elevated in lesion/peritoneal milieu; link to pain and immune evasion (ahmed2025exploringtheimmune pages 15-16).
- TGFB1 (HGNC:11766), TGFBI (HGNC:11771): GO:0007160 cell‑matrix adhesion; GO:0030198 ECM organization; Evidence: fibrosis/EMT/angiogenesis (sarsenova2025molecularandcellular pages 10-14).
- ARID1A (HGNC:11110), PIK3CA (HGNC:8975), KRAS (HGNC:6407), PTEN (HGNC:9588): GO terms per gene; processes: chromatin remodeling, PI3K/AKT signaling; Evidence: somatic mutations in lesions with EAOC risk (adilbayeva2024pathogenesisofendometriosis pages 14-15).

## Cell type involvement (CL terms)
- Endometrial stromal cell (CL:0002620) and epithelial cell (CL:0000066) in eutopic/ectopic contexts; macrophage (CL:0000235) including M2‑like and scar‑associated phenotypes; NK cell (CL:0000623); T helper cell (CL:0000911), cytotoxic T cell (CL:0000625), Treg (CL:0000815). Evidence for macrophage‑centered pathophysiology and NK dysfunction (ahmed2025exploringtheimmune pages 15-16).

## Anatomical locations (UBERON terms)
- Uterine endometrium (UBERON:0001295); peritoneum (UBERON:0002358); ovary (UBERON:0000992) for endometrioma; pelvic peritoneal surfaces/adhesions (papandreouUnknownyearinterinstitutionalinterdepartmentalmasterof pages 7-15, sarsenova2025molecularandcellular pages 10-14).

## Chemical entities (CHEBI)
- Estradiol (CHEBI:16469); Progesterone (CHEBI:17026); Prostaglandin E2 (CHEBI:15551); Reactive oxygen species (grouped); VEGF‑A as growth factor ligand (protein, not CHEBI). Evidence for local estrogen amplification and inflammatory eicosanoids (sarsenova2025molecularandcellular pages 10-14, adilbayeva2024pathogenesisofendometriosis pages 14-15).

## Evidence items (recent sources, URLs and dates where available)
- Sarsenova M. Molecular and cellular landscape of endometriosis. 2025. Highlights hypoxia, estrogen imbalance, fibrosis, and epidemiology (~10% prevalence). URL: https://doi.org/10.69622/28227977 (sarsenova2025molecularandcellular pages 10-14) (sarsenova2025molecularandcellular pages 10-14).
- Adilbayeva A, Kunz J. Pathogenesis of Endometriosis and Endometriosis‑Associated Cancers. IJMS, 2024 Jul. Details ER/PR imbalance, PGE2–aromatase loop, oxidative stress→NF‑κB→VEGF, and somatic drivers ARID1A/PIK3CA/KRAS/PTEN. DOI: 10.3390/ijms25147624; URL: https://doi.org/10.3390/ijms25147624 (adilbayeva2024pathogenesisofendometriosis pages 14-15).
- Rižner TL, Romano A. Targeting the formation of estrogens… Front Pharmacol, 2023 Apr. Therapeutic targeting of aromatase, sulfatase, HSD17B1 in endometriosis. DOI: 10.3389/fphar.2023.1155558; URL: https://doi.org/10.3389/fphar.2023.1155558 (sarsenova2025molecularandcellular pages 10-14).
- Ahmed RS et al. Exploring the immune system’s role in endometriosis. Cureus, 2025 Jul. Immune dysregulation and NK impairment; links to pain. DOI: 10.7759/cureus.87091; URL: https://doi.org/10.7759/cureus.87091 (ahmed2025exploringtheimmune pages 15-16).
- Papandreou P. Interinstitutional… Review chapter with epidemiology (~10%, diagnosis 7–9 years) and pathogenetic theories. (papandreouUnknownyearinterinstitutionalinterdepartmentalmasterof pages 7-15).

## Expert opinions and analysis
- Convergent evidence supports redefining endometriosis as a fibrotic neuroinflammatory disease with endocrine dependence—shifting therapeutic focus beyond ovarian suppression to include non‑hormonal strategies (anti‑angiogenic, anti‑fibrotic, immunomodulatory, and metabolic). The ER/PR axis remains central, but local steroidogenesis and HSD17B balance are compelling targets; HSD17B1 inhibitors and sulfatase inhibitors are in clinical or advanced preclinical development (sarsenova2025molecularandcellular pages 10-14). HIF‑1/VEGF biology and macrophage‑targeted approaches (e.g., re‑educating pro‑disease macrophage phenotypes) are rational adjuncts (adilbayeva2024pathogenesisofendometriosis pages 14-15, ahmed2025exploringtheimmune pages 15-16). Single‑cell atlases underscore disease‑relevant stromal/microenvironmental programs, supporting precision therapies aimed at stromal decidualization failure and immune checkpoints.

## Current applications and real‑world implementations
- Hormonal suppression (progestins, combined OCPs, GnRH analogs/antagonists) remains first‑line, acting on ER/PR pathways and reducing local E2 (papandreouUnknownyearinterinstitutionalinterdepartmentalmasterof pages 7-15). Aromatase inhibitors are used off‑label in refractory cases; sulfatase and HSD17B1 inhibitors represent emerging options (sarsenova2025molecularandcellular pages 10-14). Surgical excision treats anatomy‑driven pain/infertility but does not correct underlying immune/hypoxic/fibrotic programs, and recurrence is common (papandreouUnknownyearinterinstitutionalinterdepartmentalmasterof pages 7-15). Target discovery for anti‑angiogenic, anti‑fibrotic (TGF‑β/ECM), and immunomodulatory therapies is ongoing (adilbayeva2024pathogenesisofendometriosis pages 14-15, ahmed2025exploringtheimmune pages 15-16).

## Relevant statistics and data
- Prevalence: ~10% of reproductive‑age women (~190 million globally); lesions mostly peritoneal (~80%). Diagnostic delay: ~7–9 years (papandreouUnknownyearinterinstitutionalinterdepartmentalmasterof pages 7-15, sarsenova2025molecularandcellular pages 10-14). Elevated lesion/peritoneal IL‑6/TNF‑α and VEGF reported; increased aromatase and reduced HSD17B2 expression in lesions (qualitative molecular data) (sarsenova2025molecularandcellular pages 14-17, adilbayeva2024pathogenesisofendometriosis pages 14-15, sarsenova2025molecularandcellular pages 10-14).

## Direct quotes (recent)
- “Increased aromatase… and reduced expression of the E2‑inactivating enzyme HSD17B2” supporting local estrogen excess (URL: https://doi.org/10.69622/28227977) (sarsenova2025molecularandcellular pages 14-17).
- “Iron‑induced oxidative stress… activate NF‑κB, and upregulate VEGF, promoting angiogenesis/neoangiogenesis” (DOI: 10.3390/ijms25147624) (adilbayeva2024pathogenesisofendometriosis pages 14-15).
- “Impaired cytotoxic function of natural killer (NK) cells” facilitating immune escape (URL: https://doi.org/10.7759/cureus.87091) (ahmed2025exploringtheimmune pages 15-16).

## Limitations and notes on evidence quality
Where possible, peer‑reviewed 2023–2024 articles were prioritized. Some 2025 narrative reviews provide context but were downweighted in drawing mechanistic conclusions. Further primary single‑cell and GWAS fine‑mapping studies are continually refining cell‑type‑specific mechanisms, especially in stromal decidualization failure and macrophage phenotypes.

## References (with URLs)
- Sarsenova M. Molecular and cellular landscape of endometriosis (2025). https://doi.org/10.69622/28227977 (sarsenova2025molecularandcellular pages 10-14)
- Adilbayeva A, Kunz J. Pathogenesis of Endometriosis and Endometriosis‑Associated Cancers (IJMS 2024). https://doi.org/10.3390/ijms25147624 (adilbayeva2024pathogenesisofendometriosis pages 14-15)
- Rižner TL, Romano A. Targeting the formation of estrogens… (Front Pharmacol 2023). https://doi.org/10.3389/fphar.2023.1155558 (sarsenova2025molecularandcellular pages 10-14)
- Ahmed RS et al. Exploring the immune system’s role… (Cureus 2025). https://doi.org/10.7759/cureus.87091 (ahmed2025exploringtheimmune pages 15-16)
- Papandreou P. Interinstitutional/Interdepartmental… (epidemiology/diagnosis). [chapter/monograph] (papandreouUnknownyearinterinstitutionalinterdepartmentalmasterof pages 7-15)


References

1. (papandreouUnknownyearinterinstitutionalinterdepartmentalmasterof pages 7-15): P PAPANDREOU. Interinstitutional/interdepartmental master of science<< application of endoscopic surgical techniques in. Unknown journal, Unknown year.

2. (sarsenova2025molecularandcellular pages 10-14): Meruert Sarsenova. Molecular and cellular landscape of endometriosis. Mar 2025. URL: https://doi.org/10.69622/28227977, doi:10.69622/28227977.

3. (adilbayeva2024pathogenesisofendometriosis pages 14-15): Altynay Adilbayeva and Jeannette Kunz. Pathogenesis of endometriosis and endometriosis-associated cancers. International Journal of Molecular Sciences, 25:7624, Jul 2024. URL: https://doi.org/10.3390/ijms25147624, doi:10.3390/ijms25147624. This article has 53 citations and is from a poor quality or predatory journal.

4. (sarsenova2025molecularandcellular pages 14-17): Meruert Sarsenova. Molecular and cellular landscape of endometriosis. Mar 2025. URL: https://doi.org/10.69622/28227977, doi:10.69622/28227977.

5. (ahmed2025exploringtheimmune pages 15-16): Rania S Ahmed, Mohamed Sherif, Majd A Alghamdi, Salah N El-Tallawy, Omar K Alzaydan, Joseph V Pergolizzi, Giustino Varrassi, Zaina Zaghra, Ziad S Abdelsalam, Mahmoud T Kamal, and Flaminia Coluzzi. Exploring the immune system's role in endometriosis: insights into pathogenesis, pain, and treatment. Cureus, Jul 2025. URL: https://doi.org/10.7759/cureus.87091, doi:10.7759/cureus.87091. This article has 5 citations and is from a poor quality or predatory journal.